Meet Philippe Lopes-Fernandes
Executive Vice President and Chief Business Office
“Breakthroughs happen when we collaborate with partners who share our commitment to science, patients and delivering impact. Partnering to us, means following the right science, combining our strengths with those of our partners, and using our unique capabilities to ensure medicines reach patients, faster. Our alliances are deeply personal and built for the long term. Together, we know we go further.”
Philippe joined Ipsen in 2020, bringing over 20 years of leadership in global business development and acquisitions, spearheading deals across Europe, North America, and Asia, with senior BD roles at Merck KGaA. He received his degree from the Institut Supérieur de Gestion (ISG), is a French External Trade advisor (Conseiller du Commerce Extérieur), and board member of several companies. Philippe is responsible for driving Ipsen’s external innovation strategy and strengthening alliances across its key therapeutic areas of oncology, neuroscience, and rare disease. Since joining, he has played an instrumental role in delivering high-impact partnerships and M&As, contributing to the addition of over 30 new assets to Ipsen’s pipeline since 2020 and helping to strengthen its global innovation network.
Learn more about Philippe Lopes-Fernandes
Meet Mary Jane Hinrichs
SVP, Head of Early Development and Innovation
“At Ipsen, we believe that the best science is rarely developed in isolation. Through our partnerships, we have expanded our pipeline with innovative assets and cutting-edge science that have the potential to address some of the most significant unmet needs facing patients today. I am continually inspired by the expertise, entrepreneurial spirit and scientific excellence of our partners, and excited to build on this momentum as we pursue the next generation of transformative medicines together.”
Mary Jane Hinrichs, PhD, is Senior Vice President and Head of Research, External Innovation and Development Sciences (REID) at Ipsen. She leads the teams responsible for research strategy, external innovation, translational medicine, nonclinical safety, clinical pharmacology, DMPK and early development sciences, helping to identify, evaluate and advance innovative medicines across Ipsen’s focus areas. With more than 20 years of experience in pharmaceutical research and development, she has held roles across regulatory science, nonclinical development, translational medicine and clinical development at Ipsen, MedImmune/AstraZeneca and the U.S. Food and Drug Administration. Dr. Hinrichs is passionate about building partnerships and applying science to accelerate the development of transformative therapies for patients.
Contact the partnering team
At Ipsen, entering partnerships is always personal. Our team is committed to success and has the expertise to deliver it. Contact us to see how together, we can accelerate innovation for patients.
Christelle Huguet
How we work with our partners to turn a molecule into a medicine.
Partnering events
Throughout the year, Ipsen holds numerous events for and with partners. Look through our upcoming events if you are interested in our work and in partnering with us and would like to meet our team. Coming soon
Pipeline
Our robust development pipeline, backed by our expertise and external innovation strategy, support patients’ health outcomes across Oncology, Rare Disease, and Neuroscience.